コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nts suffered transient ischemic attack after cardioversion.
2 30 days (median 2 days, mean 4.6 days) after cardioversion.
3 stent atrial fibrillation undergoing planned cardioversion.
4 F recurrence in patients undergoing electric cardioversion.
5 with AF recurrence in patients who underwent cardioversion.
6 prevent recurrent atrial fibrillation after cardioversion.
7 lternative to warfarin in patients requiring cardioversion.
8 roach (delayed-cardioversion group) or early cardioversion.
9 de of torsade de pointes requiring immediate cardioversion.
10 nto 2 categories: antitachycardia pacing and cardioversion.
11 ing with only 13% of the energy required for cardioversion.
12 his profile on patients with AF that undergo cardioversion.
13 lar tachycardia during mapping that required cardioversion.
14 ditional antiarrhythmic agents for sustained cardioversion.
15 y (n = 25), presented for ibutilide (2.0 mg) cardioversion.
16 ce could provide a more effective option for cardioversion.
17 recurrence of atrial fibrillation (AF) after cardioversion.
18 ients with AF/atrial flutter referred for DC cardioversion.
19 ategy of maintenance of sinus rhythm without cardioversion.
20 gies for those patients who elect to undergo cardioversion.
21 be rare or repeatedly induce AF and require cardioversion.
22 atients had IART recurrence and 28% required cardioversion.
23 sinus rhythm by pharmacologic or electrical cardioversion.
24 n for anticoagulation for three weeks before cardioversion.
25 he management of patients with AF undergoing cardioversion.
26 ding complications and safely expedite early cardioversion.
27 tant to most chemical methods and electrical cardioversion.
28 titachycardia pacing, and AF, which requires cardioversion.
29 endent on the duration of sinus rhythm after cardioversion.
30 lar accident occurred within one month after cardioversion.
31 induce atrial contractile dysfunction after cardioversion.
32 hold protective anticoagulation for internal cardioversion.
33 ctory to standard energy direct current (DC) cardioversion.
34 n 1:1 fashion to either internal or external cardioversion.
35 , 300, and 360 J were used for transthoracic cardioversion.
36 ibrillation refractory to standard energy DC cardioversion.
37 t is resistant to conventional transthoracic cardioversion.
38 to sinus rhythm by transthoracic electrical cardioversion.
39 t thrombus resolution) is recommended before cardioversion.
40 ricular tachycardia requiring direct current cardioversion.
41 ial flutter that was treated with electrical cardioversion.
42 ected ICD patients presenting for electrical cardioversion.
43 ion does not increase the rate of successful cardioversion.
44 enefit of Mg in facilitating pharmacological cardioversion.
45 emaking, arrhythmogenesis and suppression or cardioversion.
46 fibrillation who were scheduled for electric cardioversion.
47 n) also increased from initial to subsequent cardioversions.
48 or noninferiority), and was mainly driven by cardioversions.
50 ive amount of energy required for successful cardioversion (123.3+/-55.5 versus 129.5+/-52.6 J; P=0.4
55 lso no improvement in the rate of successful cardioversion after first shock (AOR, 0.73; 95% CI, 0.51
56 difference in unadjusted rate of successful cardioversion after first shock (from 12.3% to 13.8%; P=
57 In all 14 patients in whom transthoracic cardioversion alone failed, sinus rhythm was restored wh
58 In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relap
59 gh risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion p
60 ost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on rela
63 c strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or qu
64 d directly measured refractory periods after cardioversion) also increased from initial to subsequent
66 ofetilide: 1) before elective direct current cardioversion and 2) within 24 h of restoration of SR.
67 in 20 of 23 (87%) attempts at direct current cardioversion and 7 of 22 (32%) attempts at transesopheg
68 he TEE-guided strategy had a shorter time to cardioversion and a lower rate of composite bleeding.
71 thin the same setting of the failed standard cardioversion and obviates the need to withhold protecti
72 data on efficacy of external versus internal cardioversion and on the risk of lead and device malfunc
75 e to first shock and lead to higher rates of cardioversion and survival compared with a manual strate
76 th chronic AF in humans are reversible after cardioversion and that the extent of this reversal is de
77 hythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patient
78 the treatment of atrial fibrillation: one is cardioversion and treatment with antiarrhythmic drugs to
79 ncluded use of antiarrhythmic drugs, rate of cardioversions and cardiovascular hospitalization, Atria
81 with a risk of cerebral emboli attributed to cardioversions and numerous ablation lesions in the low-
82 s alive, in sinus rhythm, with no additional cardioversions and still taking the assigned drug at one
84 after ibutilide were treated with electrical cardioversion, and 35 (90%) of 39 patients were successf
85 mary treatment in 63% of cases, 1% underwent cardioversion, and 92% were in sinus rhythm on discharge
86 rol in most patients, decreases the need for cardioversion, and antithrombotic therapy can be selecti
87 ation on the time to first shock, successful cardioversion, and patient outcomes was assessed using i
88 formation, maintenance of sinus rhythm after cardioversion, and techniques of left atrial appendage o
90 ary sinus ostium) and the long-term need for cardioversion, antithrombotic and antiarrhythmic drug th
92 icoagulation, a TEE-guided approach to early cardioversion appears to have a safety profile similar t
93 andomisation (block size four)-stratified by cardioversion approach (transoesophageal echocardiograph
98 eceiving OAC post-DCCV were found to undergo cardioversion at an earlier time after implantation (3.6
101 It may be a useful alternative to internal cardioversion because it could be done within the same s
102 ectively randomized to either direct current cardioversion before PVAI and posterior wall/septum abla
103 ignificant difference in the success rate of cardioversion between the 2 groups (86.4% versus 86.0%;
105 rdiopulmonary resuscitation, defibrillation, cardioversion, cardiac pacing, or treatments targeted at
106 and around the time of procedures including cardioversion, catheter ablation, and device implantatio
107 tilide is greater in sinus rhythm (SR) after cardioversion compared with during atrial fibrillation (
108 ents in whom early cardioversion is desired: Cardioversion could be delayed in patients with a high l
113 MIRACLE ICD (Multicenter InSync Implantable Cardioversion Defibrillation Randomized Clinical Evaluat
114 The most frequent triggering events were cardioversion/defibrillation (72, 0.6%), unplanned use o
115 he need for ICD therapies, including ATP and cardioversion/defibrillation (ICD shocks) in patients wi
118 % versus 27 +/- 18%; P = 0.01), and external cardioversion/defibrillation shocks (20% versus 65.2%; P
119 signed to receive amiodarone and undergo two cardioversions during the first three months alone (the
122 nduction block were created with a very high cardioversion efficiency but with lower energy requireme
125 ent of the placebo group, and direct-current cardioversion failed in 27.7 percent, 26.5 percent, and
127 cutive patients with ICD undergoing elective cardioversion for atrial arrhythmias at 13 centers were
129 nt trial, the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study,
131 nal cardioversion is noninferior to internal cardioversion for safety, and superior for successful re
132 assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or
133 elocities measured during sinus rhythm after cardioversion from atrial fibrillation are depressed rel
134 des of atrial fibrillation (AF) that require cardioversion from self-terminating episodes that do not
135 in atrial fibrillation, both direct-current cardioversion (Grade: 1C+) and pharmacological conversio
136 n group and in 202 of 215 (94%) in the early-cardioversion group (between-group difference, -2.9 perc
139 in 193 of 212 patients (91%) in the delayed-cardioversion group and in 202 of 215 (94%) in the early
140 d in 49 of 164 patients (30%) in the delayed-cardioversion group and in 50 of 171 (29%) in the early-
141 g of silent lead malfunction in the internal cardioversion group suggests that an internal shock atte
146 domization protocol to receive either direct cardioversion (group A) or further ablation of subsequen
147 domized to no further ablation and underwent cardioversion (Group B, n = 50) or to ablation of CFAEs
149 gorithms, antitachycardia pacing, low-energy cardioversion, high-energy shocks, and extensive diagnos
150 significant atrial arrhythmias and need for cardioversion/hospitalization for arrhythmia management.
151 ith rate-control medication only and delayed cardioversion if the atrial fibrillation did not resolve
152 rge and admitted rapidly for repeat internal cardioversion if there was spontaneous AF recurrence.
154 sulted in termination of AF without external cardioversion in 115 of the 121 patients (95%); 32 (28%)
156 iate recurrence of AF (IRAF), occurred after cardioversion in 18 of 40 patients, and IRAF was consist
159 urred spontaneously before the initiation of cardioversion in 36 of 219 patients (16%) and after card
161 h isoproterenol (up to 20 microg/min) and/or cardioversion in 45 patients with AF were identified usi
163 it-and-see approach was noninferior to early cardioversion in achieving a return to sinus rhythm at 4
165 y and efficacy of higher energy synchronized cardioversion in patients with atrial fibrillation refra
166 ssed the value of this agent in facilitating cardioversion in patients with atrial fibrillation that
168 m, but the efficacy of repetitive electrical cardioversion in restoring sinus rhythm was disappointin
171 ed during the 30 days after 5,116 successful cardioversions in 2,481 patients with neither oral antic
172 AFCL were repeated immediately before repeat cardioversions in the 17 patients who had recurrence of
173 rior anticoagulation followed by early acute cardioversion (in the absence of intracardiac thrombus)
174 view acute methods of heart rate control and cardioversion, including pharmacologic and other minimal
176 F, PVAI in sinus rhythm after direct current cardioversion is associated with higher success and shor
178 ment of therapeutic anticoagulation, whereas cardioversion is delayed in higher risk patients with th
179 ant for management of patients in whom early cardioversion is desired: Cardioversion could be delayed
182 ort-term antiarrhythmic drug treatment after cardioversion is less effective than is long-term treatm
183 rability to AF initiation 7 to 14 days after cardioversion is more dependent on persisting structural
184 ort-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment.
190 atment for supraventricular tachycardia, but cardioversion is rare in practice (5-20%), necessitating
192 with new onset AF, conversion by electrical cardioversion is the preferred approach; however, in sta
193 l fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulati
194 ither spontaneous conversion or treated with cardioversion </=7 days) or persistent (lasting >7 days)
195 echocardiography reveals no atrial thrombus, cardioversion may be performed safely after only a short
196 ardiography group also had a shorter time to cardioversion (mean [+/-SD], 3.0+/-5.6 vs. 30.6+/-10.6 d
197 est that combination therapy may be a useful cardioversion method for chronic atrial fibrillation or
198 rmed symptomatic paroxysmal AF that required cardioversion (n = 428), at least 2 episodes of AF in th
200 ation therapy is currently recommended after cardioversion of acute atrial fibrillation in patients w
207 on or atrial flutter, in patients undergoing cardioversion of atrial arrhythmias and in patients with
208 ide is a class III drug that is used for the cardioversion of atrial arrhythmias, but it can cause to
209 al amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or
213 ter trial, patients undergoing transthoracic cardioversion of atrial fibrillation were randomized to
221 omised clinical trial of anticoagulation for cardioversion of patients with non-valvular atrial fibri
222 g regimen of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (AFib)
223 performed before 25.5%, 24.1%, and 13.3% of cardioversions, of which 1.8%, 1.2%, and 1.1% were posit
225 stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and
230 d ventricular tachycardia requiring external cardioversion or appropriate implantable cardioverter de
231 There are limited data on outcomes following cardioversion or catheter ablation in AF patients treate
232 sought to investigate the outcomes following cardioversion or catheter ablation in patients with atri
233 ot translate into higher rates of successful cardioversion or survival after out-of-hospital cardiac
236 ontrol antiarrhythmic drug therapy, electric cardioversion, or catheter ablation in comparison with m
237 evere symptoms requiring hospital admission, cardioversion, or initiation/change of antiarrhythmic dr
240 lectrical cardioversion (ECV), pharmacologic cardioversion (PCV), or AF ablation and subsequent outco
242 fferent combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and
243 r), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was mos
245 hour, resulting in symptoms, or treated with cardioversion; postoperative AF excluding atrial flutter
246 story of atrial fibrillation before electric cardioversion/pulmonary vein isolation or after cardioem
247 (AFFIRM) and Rate Control Versus Electrical Cardioversion (RACE) trials that anticoagulation should
251 ctiveness models demonstrate that TEE-guided cardioversion represents a cost-effective strategy, but
252 n patients with non-valvular AF that undergo cardioversion seems to be as safe and effective as the u
254 currence of atrial fibrillation (ERAF) after cardioversion shocks delivered by permanently implanted
257 us at very low voltage and energy, with 100% cardioversion success observed for 10-ms 100-V shocks (m
259 ted OSA have a higher recurrence of AF after cardioversion than patients without a polysomnographic d
260 th AF >2 days duration undergoing electrical cardioversion, the TEE-guided group showed little differ
263 or those patients who elect to undergo acute cardioversion to achieve sinus rhythm in atrial fibrilla
264 rfarin should be continued for 1 month after cardioversion to allow for more complete recovery of atr
265 for three weeks before and four weeks after cardioversion to decrease the risk of thromboembolism.
266 n at 4 hours and again at 7 to 14 days after cardioversion to sinus rhythm included atrial effective
267 ere was an increase in AFCL from the initial cardioversion to that measured at the time of first AF r
268 ere independently associated with successful cardioversion: use of a biphasic waveform (relative risk
270 e randomized to receive Mg or placebo before cardioversion using a step-up protocol with 75, 100, 150
275 ight of the recently completed Assessment of Cardioversion Using Transesophageal Echocardiography (AC
276 (PVAI) in sinus rhythm after direct current cardioversion versus PVAI and ablation targeting complex
277 alone failed, sinus rhythm was restored when cardioversion was attempted again after the administrati
280 atment with study drug for >/=3 weeks before cardioversion was lower in D110 (76.4%) and D150 (79.2%)
290 3%) converted to sinus rhythm after repeated cardioversions, whereas the remaining 36 (66%) did so sp
291 e the former proscribe the use of electrical cardioversion while the latter provide this precise trea
292 r at least two attempts at standard external cardioversion with 360 J were included in the study.
294 udy was to assess the efficacy and safety of cardioversion with combination therapy in patients with
295 ent is aimed at heart rate control, elective cardioversion with drugs or electrical means, and antico
296 e randomly assigned to undergo transthoracic cardioversion with or without pretreatment with 1 mg of
297 cardioversion anticoagulation versus delayed cardioversion with pre- and postanticoagulation are appr
299 were in arrhythmia for 196+/-508 days before cardioversion, with a left ventricular ejection fraction